Advanced Accelerator Applications Sa ETF Company Profile

Description

Advanced Accelerator Applications S.A., a radiopharmaceutical company, engages in the development, production, and commercialization of molecular nuclear medicine diagnostic and therapeutic products primarily in France, Italy, the United Kingdom, Spain, Portugal, Israel, Switzerland, Germany, and Canada. It provides positron emission tomography (PET) products, including Gluscan, a branded 18-fluorodeoxyglucose PET imaging agent that assists in the diagnosis of serious medical conditions primarily in oncology through assessing glucose metabolism; IASOflu, which images bone metastases; IASOdopa to diagnose Parkinson’s disease and tumors in various indications; and IASOcholine for diagnosing prostate cancer. The company also offers single-photon emission computed tomography (SPECT) products comprising Tetrakis (2-methoxyisobutyl isonitrile) copper (I) tetrafluoroborate, a cardiac imaging agent for myocardial exploration, localization of parathyroid tissue, and breast cancer diagnosis; and Leukokit, a single-use medical device to carry out separation and labeling of autologous leukocytes. Its products that are in clinical development comprise Lutathera, a Lu-177 labeled somatostatin analogue peptide that has been approved for the treatment of neuro endocrine tumors (NETs); Somakit, a sterile and lyophilized reconstitution kit for the labeling of somatostatin analogue peptides, as well as for the localization of primary and/or metastatic lesions of GEP-NETs; and Annexin V-128, a SPECT radiopharmaceutical product candidate to detect early cell stress and apoptosis to assess programmed cell death in various pathological conditions, including rheumatoid arthritis. The company was founded in 2002 and is headquartered in Saint Genis Pouilly, France.